-
Doctors' benevolence, excellence: "2022 Breast Cancer Elite Practice and Exchange Project - Weihai Station" ended successfully
Time of Update: 2022-11-14
Case 3 Sharing: Dr. Mao Yan (Breast Disease Diagnosis and Treatment Center, The Affiliated Hospital of Qingdao University)The patient, 43 years old, was diagnosed with breast malignancy (left, cT2N1M1), stage IV, Luminal type B, bone secondary malignancy, PR(-), Her-2(1+)) in 2018.
-
SMC approves the first immunotherapy combination (Nivolumab combined with ipilmumab) for patients with rare-mutated advanced colorectal cancer
Time of Update: 2021-12-24
Recently, Bristol-Myers Squibb (BMS) announced that the Scottish Pharmaceutical Union (SMC) has accepted Nivolumab in combination with ipilmumab as a late mismatch repair defect (dMMR) or high microsatellite instability (MSIH)Treatment options for adults with colorectal cancer , these patients have failed previous fluoropyrimidine-based chemotherapy, and the therapy is used by the NHS in Scotland .
-
"Beidou" joins hands in medical treatment for the first time, empowering critical emergency first aid to "speed up again
Time of Update: 2021-07-31
Shanghai Tenth Hospital Unveiled the Inauguration of the Neurological Intensive Wisdom Medical Diagnosis and Treatment Center "Beidou" joins hands in medical treatment for the first time, em
-
Three tables: How to adjust the administration during the perioperative period for patients who encounter long-term oral hormones
Time of Update: 2021-05-21
Patients with secondary adrenal insufficiency caused by pituitary and hypothalamic diseases and exogenous hormone therapy decrease ACTH, but continue to secrete aldosterone under the action of renin.
Dexamethasone has no mineralocorticoid activity and cannot provide hormone coverage under stress for patients with primary adrenal insufficiency.
-
The international perspective | Professor Mark A. Schroeder analyzes the three major research advances in GVHD
Time of Update: 2021-03-24
In 2017, based on the results of a phase II study of PCYC-1129-CA (NCT02195869) in patients with severe oral and skin cGVHD, Ibrutinib was approved by the FDA for the second-line treatment of glucocorticoid-resistant cGVHD.
The patients were randomly divided into two groups and received rucotinib/BAT+glucocorticoid ± calcineurin inhibitor (CNI) treatment.
-
From targeting to immune non-small cell lung cancer ushers in multiple breakthroughs
Time of Update: 2021-03-09
Kilickap and colleagues reported the results of an empower-Lung Phase III clinical trial that assessed the efficacy of cemiplimab and platinum double chemotherapy as a first-line treatment in 437 patients with PD-L1 expression ≥50% of patients with advanced NSCLC.
-
Bayer PI3K inhibitors identified by FDA as breakthrough therapy for treatment of lymphoma
Time of Update: 2020-06-09
According to the World Cancer Research Foundation (WCRF), non-Hodgkin lymphoma (NHL) is the most common blood cancer in the world, accounting for 3% of all cancer patients According to the American Ca
-
stage a comeback! Gilead talks with the Chinese government about sovaldi's entry into China
Time of Update: 2015-08-06
Source: on August 6, 2015, Biovalley said that "there are many kinds of medicine red" The most obvious example is Gilead company, which has been enjoying unlimited scenery in the past two years In les
